Takeda Pharmaceutical Company Ltd.
December 9, 2021
In June 2020, Neurocrine Biosciences entered into a strategic collaboration with Takeda to develop and commercialize compounds in Takeda’s early-to-mid-stage psychiatry pipeline. Specifically, Neurocrine Biosciences received an exclusive license for seven Takeda pipeline programs, including three clinical stage assets, which we are studying in schizophrenia, treatment-resistant depression, and anhedonia.
